Astria Therapeutics (NASDAQ:ATXS) Shares Pass Below Fifty Day Moving Average – What’s Next?

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) crossed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $8.26 and traded as low as $6.99. Astria Therapeutics shares last traded at $7.06, with a volume of 204,454 shares changing hands.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Citizens Jmp upgraded shares of Astria Therapeutics to a “strong-buy” rating in a research report on Friday, January 31st. Oppenheimer lifted their target price on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research note on Thursday, November 14th. JMP Securities initiated coverage on shares of Astria Therapeutics in a research note on Friday, January 31st. They set an “outperform” rating and a $26.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of Astria Therapeutics in a research note on Thursday, January 23rd. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $25.67.

Astria Therapeutics Trading Up 0.6 %

The firm has a market cap of $398.40 million, a PE ratio of -3.38 and a beta of 0.67. The company’s 50-day moving average is $8.26 and its 200 day moving average is $10.09.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Fcpm Iii Services B.V. bought a new position in Astria Therapeutics during the 4th quarter valued at about $25,680,000. FMR LLC lifted its holdings in Astria Therapeutics by 29.2% during the 3rd quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock valued at $86,123,000 after purchasing an additional 1,767,714 shares during the last quarter. Vestal Point Capital LP lifted its holdings in Astria Therapeutics by 23.1% during the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock valued at $44,040,000 after purchasing an additional 750,000 shares during the last quarter. Redmile Group LLC bought a new position in Astria Therapeutics during the 3rd quarter valued at about $3,423,000. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Astria Therapeutics by 152.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 314,265 shares of the biotechnology company’s stock valued at $3,460,000 after purchasing an additional 189,727 shares during the last quarter. 98.98% of the stock is currently owned by institutional investors and hedge funds.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.